Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance Therapy
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
CONTEXT: In the Trilège trial, following induction with a zidovudine, lamivudine, and indinavir regimen, human immunodeficiency virus (HIV) replication was less suppressed by 2-drug maintenance therapy than by triple-drug therapy. OBJECTIVE: To identify mechanisms of virologic failure in the 3 arms of the Trilège trial. DESIGN: Case-control study conducted from February to October 1998. SETTING: Three urban hospitals in Paris, France. PATIENTS: Fifty-eight case patients with virologic failure (HIV RNA rebound to >500 copies/mL in 2 consecutive samples) randomized to 3 therapy groups: triple drug (zidovudine, lamivudine, and indinavir), 8; zidovudine-lamivudine, 29; and zidovudine-indinavir, 21; the case patients were randomly matched with 58 control patients with sustained viral suppression. MAIN OUTCOME MEASURES: At virologic failure (S1 sample) and 6 weeks later (S2 sample), assessment of protease and reverse transcriptase gene mutations, plasma indinavir level, and degree of viral load rebound; pill count during induction and maintenance periods. RESULTS: Only 1 primary resistance mutation, M184V, was detected in S1 plasma samples from 4 of 6 patients in the triple-drug and in all 22 in the zidovudine-lamivudine therapy groups and in S2 plasma samples from 3 of 6 in the triple-drug and 20 of 21 in the zidovudine-lamivudine groups. Of controls, M184V was detected in 11 of 13 S1 plasma samples and in 10 of 11 S2 plasma samples. Indinavir levels were undetectable in all S1 samples but 2 in 7 triple-drug cases tested and in the expected range in 11 of 18 S1 and 5 of 12 S2 zidovudine-indinavir case plasma samples tested. Maintenance adherence rates were lower for cases vs controls for zidovudine (P = .05) and indinavir (P = .05). Low indinavir levels, lower adherence rates for zidovudine (P = .04) and lamivudine (P = .03), and rebound to near-baseline values suggested adherence as cause of early failure for 4 of 8 triple-drug cases. In the zidovudine-lamivudine arm, for which case and control adherence rates did not differ significantly (P = .96), most failures occurred late with low rebound, suggesting suboptimal drug potency. In the zidovudine-indinavir arm, virologic failures may be related to both mechanisms. CONCLUSIONS: During the maintenance phase early and late virologic failures appeared to be related more to problems of adherence and antiretroviral treatment potency, respectively, than to selection of resistant mutant viruses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy
Larder, B. A., Kemp, S. D., & Harrigan, P. R. (1995) · Science · doi:10.1126/science.7542804 · Cited by 623
Hirsch, M. S., Conway, B., D'Aquila, R. T., Johnson, V. A., Brun-Vézinet, F., Clotet, B., Demeter, L. M., Hammer, S. M., Jacobsen, D. M., Kuritzkes, D. R., et al. (1998) · JAMA · doi:10.1001/jama.279.24.1984 · Cited by 563
Eron, J. J., Benoit, S. L., Jemsek, J., MacArthur, R. D., Santana, J., Quinn, J. B., Kuritzkes, D. R., Fallon, M. A., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332502 · Cited by 531
Condra, J. H., Holder, D. J., Schleif, W. A., Blahy, O. M., Danovich, R. M., Gabryelski, L. J., Graham, D. J., Laird, D., Quintero, J. C., Rhodes, A., et al. (1996) · Journal of Virology · doi:10.1128/jvi.70.12.8270-8276.1996 · Cited by 405
Havlir, D. V., Marschner, I. C., Hirsch, M. S., Collier, A. C., Tebas, P., Bassett, R. L., Ioannidis, J. P. A., Holohan, M. K., Leavitt, R., Boone, G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810293391801 · Cited by 307
Stuyver, L., Wyseur, A., Rombout, A., Louwagie, J., Scarcez, T., Verhofstede, C., Rimland, D., Schinazi, R. F., & Rossau, R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.284 · Cited by 234
Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy
Nijhuis, M., Boucher, C. A. B., Schipper, P., Leitner, T., Schuurman, R., & Albert, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14441 · Cited by 160
Reijers, M. H. E., Weverling, G. J., Jurriaans, S., Wit, F. W. N. M., Weigel, H. M., ten Kate, R. W., Mulder, J. W., Frissen, P. H. J., van Leeuwen, R., Reiss, P., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)06193-5 · Cited by 154
Cited by
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Wells, K. B., Sherbourne, C., Schoenbaum, M., Duan, N., Meredith, L., Unützer, J., Miranda, J., Carney, M. F., & Rubenstein, L. V. (2000) · JAMA · doi:10.1001/jama.283.2.212 · Cited by 1,021
Clavel, F., & Hance, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm2ra025195 · Cited by 800
Hirsch, M. S., Brun-Vézinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., et al. (2000) · JAMA · doi:10.1001/jama.283.18.2417 · Cited by 766
Arnsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevitch, M. N., Chang, C., Buono, D., Eckholdt, H., Howard, A. A., & Schoenbaum, E. E. (2001) · Clinical Infectious Diseases · doi:10.1086/323201 · Cited by 637
Thompson, M. A., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., Orrell, C., Altice, F. L., Bangsberg, D. R., Bartlett, J. G., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-11-201206050-00419 · Cited by 582
Hirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Hirsch, M. S., Brun‐Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., D’Aquila, R. T., Demeter, L. M., Hammer, S. M., Johnson, V. A., Loveday, C., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/375597 · Cited by 514
Mannheimer, S., Friedland, G., Matts, J., Child, C., Chesney, M., & Terry Beirn Community Programs for Clinical Research on, A. I. D. S. (2002) · Clinical Infectious Diseases · doi:10.1086/339074 · Cited by 512
Hogg, R. S., Heath, K., Bangsberg, D., Yip, B., Press, N., O'Shaughnessy, M. V., & Montaner, J. S. G. (2002) · AIDS · doi:10.1097/00002030-200205030-00012 · Cited by 425
Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection
Robbins, G. K., De Gruttola, V., Shafer, R. W., Smeaton, L. M., Snyder, S. W., Pettinelli, C., Dubé, M. P., Fischl, M. A., Pollard, R. B., Delapenha, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030264 · Cited by 351
Detrimental Effects of Continued Illicit Drug Use on the Treatment of HIV-1 Infection
Lucas, G. M., Cheever, L. W., Chaisson, R. E., & Moore, R. D. (2001) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200107010-00006 · Cited by 350
Adherence is not a barrier to successful antiretroviral therapy in South Africa
Orrell, C., Bangsberg, D. R., Badri, M., & Wood, R. (2003) · AIDS · doi:10.1097/00002030-200306130-00011 · Cited by 341
Safren, S. A., W. Otto, M., Worth, J. L., Salomon, E., Johnson, W., Mayer, K., & Boswell, S. (2001) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(00)00091-7 · Cited by 327
Weidle, P. J., Malamba, S., Mwebaze, R., Sozi, C., Rukundo, G., Downing, R., Hanson, D., Ochola, D., Mugyenyi, P., Mermin, J., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09330-3 · Cited by 315
Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance
Shafer, R. W. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.247-277.2002 · Cited by 314
Spire, B., Duran, S., Souville, M., Leport, C., Raffi, F., & Moatti, J.-P. (2002) · Social Science & Medicine · doi:10.1016/s0277-9536(01)00125-3 · Cited by 296
Van Dyke, R. B., Lee, S., Johnson, G. M., Wiznia, A., Mohan, K., Stanley, K., Morse, E. V., Krogstad, P. A., Nachman, S., Pediatric AIDS Clinical Trials Group Adherence Subcommittee, et al. (2002) · Pediatrics · doi:10.1542/peds.109.4.e61 · Cited by 291
Horberg, M. A., Silverberg, M. J., Hurley, L. B., Towner, W. J., Klein, D. B., Bersoff-Matcha, S., Weinberg, W. G., Antoniskis, D., Mogyoros, M., Dodge, W. T., et al. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318160d53e · Cited by 264
Kleeberger, C. A., Phair, J. P., Strathdee, S. A., Detels, R., Kingsley, L., & Jacobson, L. P. (2001) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200101010-00012 · Cited by 254
Baert, L., van ‘t Klooster, G., Dries, W., François, M., Wouters, A., Basstanie, E., Iterbeke, K., Stappers, F., Stevens, P., Schueller, L., et al. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.03.006 · Cited by 224
Hermankova, M. (2001) · JAMA · doi:10.1001/jama.286.2.196 · Cited by 216
Provider Assessment of Adherence to HIV Antiretroviral Therapy
Bangsberg, D. R., Hecht, F. M., Clague, H., Charlebois, E. D., Ciccarone, D., Chesney, M., & Moss, A. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200104150-00005 · Cited by 203
Modelling the Impact of Antiretroviral Use in Resource-Poor Settings
Baggaley, R. F., Garnett, G. P., & Ferguson, N. M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030124 · Cited by 168
“Duration before death with AIDS (all infection categories) 9 mo [32,33]”
BackgroundPrediction of adherence to antiretroviral therapy: A one-year longitudinal study
Godin, G., Côté, J., Naccache, H., Lambert, L. D., & Trottier, S. (2005) · AIDS Care · doi:10.1080/09540120412331291715 · Cited by 166
“Non-adherence or inadequate adherence have resulted in virologic and therapeutic failures (Descamps et al., 2000; Knobel et al., 2001; Le Moing et al., 2002).”
BackgroundFeeney, G. F. X., Connor, J. P., Young, R. M., Tucker, J., & Czajkowski, F. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00326.x · Cited by 13
Mimtsoudis, I., Tsachouridou, O., Akinosoglou, K., & Metallidis, S. (2024) · Viruses · doi:10.3390/v16091392 · Cited by 13
“The diminished fitness of viruses containing the M184V mutation has been shown both in vitro [56,57] and in clinical studies [58–61].”
Background
Metadata
- Authors
- Descamps, D.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2000-01-12
- Volume
- 283
- Issue
- 2
- Pages
- 205
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2126983724
- Cited by
- 367
- References
- 13
- FWCI
- 49.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.